PD-L1 Did Not Predict Immunotherapy Benefit in CC ...Middle East

Medscape - News
PD-L1 Did Not Predict Immunotherapy Benefit in CC
A post hoc analysis of the BEATcc trial showed that atezolizumab plus chemotherapy and bevacizumab provided clinical benefit regardless of PD-L1 status. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( PD-L1 Did Not Predict Immunotherapy Benefit in CC )

Apple Storegoogle play

Also on site :

Most viewed in News


Latest News